Epstein David R

About Epstein David R

David R. Epstein is a seasoned life sciences executive with a career built at the intersection of corporate strategy, drug development, and biotechnology value creation. He currently serves as an Executive Partner at Flagship Pioneering and has played senior governance roles across several innovative portfolio companies, including Axcella Health Inc. and Evelo Biosciences, Inc. His board and leadership experience reflects deep familiarity with science-driven organizations, capital-intensive growth, and the development of emerging therapeutic platforms. Epstein’s most prominent operating role was Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG, which he led from 2010 until mid-2016. Prior to becoming CEO, he helped establish and grow Novartis’s Oncology and Molecular Diagnostics businesses. During his tenure, Novartis’s oncology franchise expanded significantly and became one of the largest in the world. That track record is often cited as evidence of his ability to build complex pharmaceutical businesses, manage large-scale innovation efforts, and execute across global markets. Across his career, Epstein has been associated with responsibilities spanning research and development, commercialization, drug portfolio strategy, business development, and executive leadership. In the U.S. public company context, he is widely recognized for his board-level involvement in biotechnology companies, where he has contributed perspective on scientific priorities, strategic positioning, and disciplined execution. His affiliations with Axcella Health and Evelo Biosciences underscore his continued presence in the biotech ecosystem and his focus on companies pursuing novel therapeutic approaches. For corporate and investor audiences, David R. Epstein stands out as a senior healthcare executive with a strong record in building and guiding innovative life sciences businesses, particularly in settings where scientific ambition must be matched with operational rigor and long-term strategic vision.